Spike S1 (B.1.617 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay Kit

Catalog #
$1,070 *
Size: 384 reactions
*US Pricing only. For international pricing, please contact your local distributor.

The Spike S1 (B.1.617 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 (B.1.617 Variant) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).

SARS-CoV-2 inhibition kit, ACE2 inhibition kit, SARS TR-FRET kit, ACE2 homogenous kit, B.1.617 Variant, B.1.617 assay kit
Product Info
Storage and Usage
Assay Kit Format
Supplied As
Homogeneous 384 reaction format
Materials Required But Not Supplied

Fluorescence microplate reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET)
Adjustable micropipettor and sterile tips

Catalog # Name Amount Storage
100705 ACE2, His-Tag, Eu-labeled* 2 x 2 µg -80°C
101123 Spike S1* (B.1.617 Variant), Avi-His-tag, Biotin Labeled (16-685) (SARS-CoV-2) 2 x 25 µg -80°C
  Dye-labeled acceptor 3 x 10 µl -20°C
79953 3x ACE2-Spike TR-FRET Buffer 4 ml -20°C
79969 384-well white microplate 1 Room Temp

*The initial concentration of both ACE2 and Spike S1 is lot-specific and will be indicated on the tube containing the protein.


The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection.

The SARS-CoV-2 variant B.1.617 was originally discovered in India. This variant was the precursor to the B.1.617.1 (Kappa) and the B.1.617.2 (Delta) variants. It contains mutations L452R, E484Q, D614G and P681R.


1. Hoffmann, M. et al. Cell, 181:1-10
2. Yan, R. et al. Science 367(6485):1444-1448